Motevasseli Tahmineh, Mohammadi Saeed, Abdi Fatemeh, Freeman William R
Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.
J Ophthalmic Vis Res. 2021 Oct 25;16(4):670-675. doi: 10.18502/jovr.v16i4.9757. eCollection 2021 Oct-Dec.
Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome and provided an evolution in the treatment of retinal disease. The current four anti-VEGF drugs - pegaptanib, ranibizumab, aflibercept, and bevacizumab - have been administered for many years. A new anti-VEGF agent, brolucizumab, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for the treatment of wet age-related macular degeneration. Brolucizumab is a novel single-chain fragment variable antibody that inhibits all isoforms of VEGF-A and has been suggested to have more tissue penetration. Despite all the benefits, there are some reports of serious side effects that need to be understood in managing patients. Brolucizumab has been reported to cause occlusive retinal vasculitis in the setting of intraocular inflammation, which has not been seen in other anti-VEGF medications. A PubMed and Scopus search was performed and all article types were included. In the present article, we have reviewed the reported side effects of brolucizumab.
年龄相关性黄斑变性及其并发症——视网膜下新生血管形成，是导致中心视力进行性、不可逆损害的常见原因。抗血管内皮生长因子（抗VEGF）疗法改善了视力预后，并为视网膜疾病的治疗带来了进展。目前的四种抗VEGF药物——培加尼布、雷珠单抗、阿柏西普和贝伐单抗——已应用多年。一种新型抗VEGF药物布罗芦izumab于2019年末获美国食品药品监督管理局（FDA）批准，用于治疗湿性年龄相关性黄斑变性。布罗芦izumab是一种新型单链可变片段抗体，可抑制VEGF-A的所有亚型，据推测其具有更强的组织穿透性。尽管有诸多益处，但仍有一些关于严重副作用的报道，在治疗患者时需要了解这些情况。据报道，布罗芦izumab可在眼内炎症情况下引发闭塞性视网膜血管炎，而其他抗VEGF药物未见此情况。我们进行了PubMed和Scopus检索，并纳入了所有文章类型。在本文中，我们回顾了布罗芦izumab已报道的副作用。
